To analyze the disease spectrum, clinical characteristics, treatment strategies, and maternal-fetal outcomes of pregnancy complicated with malignancy, so as to provide evidence for multidisciplinary collaboration in clinical practice to improve the diagnosis rate and optimize maternal-fetal prognosis.

A retrospective analysis was conducted on 50 cases of pregnancy associated with malignancy admitted to The First Affiliated Hospital of Army Medical University (Third Military Medical University) from February 2015 to August 2025. The tumor types, clinical manifestations, diagnostic methods, treatment strategies, and pregnancy outcomes were summarized.

Among the 50 patients with malignancies, the most common were hematological tumors(17/50, 34.0%), followed by cervical cancer(6/50, 12.0%), breast cancer(5/50, 10.0%), and ovarian cancer(4/50, 8.0%).Two cases were definitively diagnosed after delivery. Twenty-two patients terminated their pregnancy (22/50, 44.0%), including 21 cases of pregnancy termination and 1 case of death after definitive diagnosis. Twenty-six patients continued their pregnancies (26/50, 52.0%), including 17 preterm births and 9 full-term deliveries. Among those who continued pregnancy, 12 (12/50, 24.0%) received treatment during gestation (5 underwent surgery and 7 received chemotherapy). As of the follow-up date, 39 patients survived (78.0%), 7 died (14.0%), and 4 were lost to follow-up (8.0%). Of the 28 newborns, 2 were lost to follow-up, and the remaining survived with no obvious abnormalities in growth and development.

Clinical manifestations of malignant tumors during pregnancy are easily confused with physiological changes of pregnancy. Early diagnosis relies on vigilance toward abnormal symptoms and targeted examinations. Treatment should be individualized by a multidisciplinary team based on tumor type, stage, and gestational age. Malignant tumor is not an indication for pregnancy termination. With appropriate management such as standardized surgery and neoadjuvant chemotherapy, tumor control can be achieved while continuing pregnancy to obtain healthy offspring, realizing the dual goals of maternal treatment and fetal safety.

To explore the monitoring and prognosis of pregnancies complicated with breast cancer.

A retrospective analysis was conducted on 34 patients with pregnancy complicated with breast cancer who were treated at our hospital from January 1, 2006 to March 31, 2025. Their clinical characteristics, pregnancy outcomes, and prognosis were analyzed.

The 34 patients ranged in age from 23 to 42 years, with a mean age of 32.56±5.58 years. Most cases were diagnosed in the second and third trimesters (28 cases, 82.35%), of which 11 were advanced breast cancer. The double-negative rate (both progesterone receptor and estrogen receptor negative) was 35.49% (11 cases). Among the 34 patients, 28 chose to continue their pregnancy. Of these 28 patients, 3 underwent radical mastectomy during pregnancy: one delivered at term, and two delivered at 33 weeks and 31^{+ 3} weeks of gestation, respectively. 2 patients received surgery combined with chemotherapy and both delivered at term. 15 patients received chemotherapy alone during pregnancy, all using the EC regimen (epirubicin + cyclophosphamide), with an average prolongation of gestation of 13.30±5.52 weeks and a mean gestational age at delivery of 36.35±1.78 weeks. 8 patients received no treatment. Newborns were followed up and showed normal growth and development. After induced labor or delivery, all patients received comprehensive treatment for breast cancer. To date, 28 patients have survived, three were lost to follow-up, and three died due to systemic metastasis.

Surgery and/or chemotherapy are relatively safe for pregnancies complicated with breast cancer during the second and third trimesters, and the neonatal outcomes are favorable.

To investigate the clinical characteristics, diagnosis, treatment, and causes of death in patients with pregnancy complicated by tumors.

A retrospective analysis was conducted on the clinical data of 6 maternal death cases involving pregnancy complicated by tumors in Fujian Province from January to December 2021.

Among the 6 cases, three were gastric cancer, one was pulmonary adenocarcinoma, one was pulmonary lymphangioleiomyomatosis, and one was rhabdomyosarcoma. 4 cases were misdiagnosed or missed (including 1 case where the patient concealed her medical history and refused specialized examinations). Distant or systemic metastasis occurred in 3 cases. Only one patient was eligible to receive tumor-specific treatment, while the others received only symptomatic and supportive care. Two maternal deaths occurred after termination of pregnancy by cesarean section, two occurred following intrauterine fetal death, and the remaining two occurred during pregnancy. All six patients died due to tumor progression.

Tumors complicating pregnancy are characterized by insidious symptoms, high rates of misdiagnosis and missed diagnosis, advanced tumor stages at diagnosis, rapid progression, and poor prognosis. In clinical practice, multidisciplinary collaboration should be strengthened to improve outcomes through early diagnosis, timely treatment, and individualized decision-making.

To explore the clinical manifestations, diagnosis, treatment options, and maternal and infant outcomes of pulmonary embolism in early and middle pregnancy.

Based on the clinical data of 1 case admitted to Peking University Shenzhen Hospital and 18 cases reported in domestic and international literature of pulmonary embolism before 20 weeks of gestation, the treatment plans and maternal and infant outcomes were retrospectively analyzed.

The patient was a 26-year-old woman at 18^{+ 2} weeks of gestation, admitted to the Department of Respiratory Medicine, Peking University Shenzhen Hospital on April 28, 2022, with a complaint of " chest distress for 15 hours". Chest CT pulmonary angiography suggested acute massive pulmonary embolism, and heparin was administered for anticoagulation. On the morning of April 30, the condition was considered stable, and the treatment was switched to enoxaparin sodium. However, that night, chest distress and dyspnea recurred with increased pulmonary artery pressure. Emergency interventional thrombectomy and thrombolysis were performed. After the procedure, severe antithrombin Ⅲ deficiency (activity 24%) complicated by heparin resistance occurred. After infusion of fresh frozen plasma, adjustment of unfractionated heparin dosage, and bridging with warfarin, the patient improved and was discharged. The pregnant woman was admitted for delivery at 39^{+ 5} weeks of gestation on September 26, 2022. On September 28, a cervical dilation balloon was placed followed by intravenous oxytocin for induction of labor, and she eventually delivered a healthy live infant vaginally. A total of 18 cases of pregnant women with pulmonary embolism within 20 weeks of gestation were identified from the PubMed literature. Together with the present case, the clinical manifestations in the 19 cases were as follows: dyspnea (13/19), chest pain/chest tightness (9/19), syncope/unconsciousness (3/19). Among these 19 patients, 16 were diagnosed by chest CT, CT pulmonary angiography, or lung ventilation/perfusion scan, 2 by transthoracic echocardiography, and 1 did not mention the examination method. Of these, 14 patients received heparin or low-molecular-weight heparin before thrombolysis or surgery. Three cases underwent pulmonary embolectomy, 10 received systemic thrombolysis, and 6 received catheter-directed therapy.

Common clinical manifestations of pulmonary embolism in pregnancy include dyspnea and chest pain, and diagnosis mainly relies on CT pulmonary artery angiography. Treatment should follow the principle of individualization and be decided by a multidisciplinary team. For patients with hemodynamic instability or high risk, catheter-directed therapy can be considered as a priority reperfusion strategy because of its high efficiency and relatively low bleeding risk. Standard anticoagulant management and perinatal planning are key to achieving good maternal and infant outcomes.

To analyze the related factors and pregnancy outcomes of patients with subchorionic hematoma (SCH) who experienced spontaneous abortion.

(1) A retrospective analysis was conducted on the clinical data of 491 patients with SCH who attended Dongguan Maternal and Child Health Hospital from February 2022 to August 2022. Pregnancy outcomes were followed up and relevant data were collected. (2) Based on the ratio of SCH volume to gestational sac volume, the 491 patients were divided into three groups: Group A (<20%, n=203), Group B (20%~50%, n=158), and Group C (>50%, n=130). (3) The gestational age at SCH onset, duration of SCH, pregnancy outcomes, and pregnancy complications were analyzed among the three groups.

The gestational age at SCH onset in the three groups was (8.51±1.71) weeks, (7.11±1.30) weeks, and (6.12±1.08) weeks, respectively (P<0.001). The duration of SCH was (3.06±1.98) weeks, (3.64±2.14) weeks, and (4.29±2.79) weeks, respectively (P<0.001), with statistically significant differences. The risk of spontaneous abortion in group B was 2.99 times that in group A (95%CI: 1.19~7.51, P=0.002), and the risk in group C was 7.51 times that in group A (95%CI: 3.18~17.70, P<0.001); The spontaneous abortion rate increased significantly with the increased in the ratio of SCH volume to gestational sac volume (3.9% vs. 9.5% vs. 22.35, P<0.001). There was no statistically significant difference in the incidence of pregnancy and childbirth complications (including preeclampsia, premature rupture of membranes, placental adhesion, and postpartum hemorrhage) among the three groups (P>0.05). The risk of spontaneous abortion in SCH patients with intrauterine lesions (including endometrial polyps, submucosal fibroids and intrauterine adhesions) was 3.46 times higher than that without such intrauterine lesions (95%CI: 1.54~7.78, P=0.003). The risk of spontaneous abortion decreased by 0.43 times for each additional term delivery (95%CI: 0.24~0.77; P=0.004). Among the 491 SCH patients, 52 (10.59%) experienced spontaneous abortion, of whom 25 underwent multiplex ligation-dependent probe amplification testing of chorionic villus. The tests revealed abnormal results in 17 patients.

In conclusion, larger SCHs appears at an earlier gestation age and persists longer. As the ratio of SCH to gestational sac volume increases, the spontaneous abortion rate increases significantly. Patients with SCH and intrauterine lesions have a significantly increased risk of spontaneous abortion, while patients with SCH who have previously delivered at term have a significantly reduced risk.